TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9893073

Group type: EXPERIMENTAL
Intervention: Exercise program (6 months)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 250
Study: 7776087

Group type: EXPERIMENTAL
Intervention: Yale Observation Scale (YOS) score > 10
Number of subjects: 6611

Group type: EXPERIMENTAL
Intervention: Yale Observation Scale (YOS) score
Number of subjects: 6611
Study: 2185404

Group type: EXPERIMENTAL
Intervention: Molsidomine (2 X 8 mg/d)
Number of subjects: 393

Group type: COMPARATOR
Intervention: Nifedipine (3 X 20 mg/d) and acetylsalicylic acid (1 X 500 mg/d)
Number of subjects: 393

Group type: EXPERIMENTAL
Intervention: SIN‐I (0.5 mg)
Number of subjects: 393
Study: 6113802

Group type: EXPERIMENTAL
Intervention: Cimetidine 200 mg by intramuscular injection one hour before surgery
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (no cimetidine)
Number of subjects: 50
Study: 31396203

Group type: EXPERIMENTAL
Intervention: Pemphigus patients
Number of subjects: 1985

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 1985

Group type: EXPERIMENTAL
Intervention: Pemphigus patients in the 1st year post-diagnosis
Number of subjects: 1985

Group type: EXPERIMENTAL
Intervention: Pemphigus patients managed with systemic medications
Number of subjects: 1985
Study: 28346569

Group type: EXPERIMENTAL
Intervention: 4x100,000 IU cholecalciferol every 2 weeks (treatment group)
Number of subjects: 111

Group type: COMPARATOR
Intervention: Individualized regimen according to baseline 25(OH)VitD level (control group)
Number of subjects: 111
Study: 26519165

Group type: EXPERIMENTAL
Intervention: Interactive educational intervention
Number of subjects: 58

Group type: COMPARATOR
Intervention: Didactic educational intervention
Number of subjects: 58
Study: 23523254

Group type: EXPERIMENTAL
Intervention: Intravenous tezosentan (5 mg/h during surgery and up to 24 hours afterwards at 1 mg/h)
Number of subjects: 274

Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 274
Study: 20938670

Group type: EXPERIMENTAL
Intervention: Postoperative radiotherapy 7 days a week (p-CAIR)
Number of subjects: 279

Group type: COMPARATOR
Intervention: Postoperative radiotherapy 5 days a week (CF)
Number of subjects: 279
Study: 19627359

Group type: EXPERIMENTAL
Intervention: Resin-coated with Clearfil Tri-S Bond
Number of subjects: 2

Group type: COMPARATOR
Intervention: Non-coated (control)
Number of subjects: 2
Study: 17076605

Group type: EXPERIMENTAL
Intervention: CO2 laser technique
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional technique (scalpel)
Number of subjects: 40
Study: 15025607

Group type: EXPERIMENTAL
Intervention: Ciaglia Blue Rhino (CBR)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Guide Wire Dilating Forceps (GWDF)
Number of subjects: 53
Study: 11318966

Group type: EXPERIMENTAL
Intervention: Minidose warfarin (1 mg/day)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Low hemoglobin (<10.5 g/dL)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Low international normalized ratio (<1.00)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Diabetes
Number of subjects: 105
Study: 9398954

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 38

Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 38
Study: 18415463

Group type: EXPERIMENTAL
Intervention: 75 mg diclofenac
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: 600 mg apazone
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Combination of 75 mg diclofenac and 600 mg apazone
Number of subjects: 112

Group type: COMPARATOR
Intervention: Placebo (50 ml NaCl 0.9%)
Number of subjects: 112
Study: 3365857

Group type: EXPERIMENTAL
Intervention: High-dose food allergen intake (one egg and one litre of milk daily)
Number of subjects: 165

Group type: COMPARATOR
Intervention: Low-dose food allergen intake (diet free from hens' egg and cows' milk)
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Maternal diet (varied diets)
Number of subjects: 165
Study: 29698111

Group type: EXPERIMENTAL
Intervention: Arachidonic acid (ARA) supplementation, 1.5 g/day for 4 weeks
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo (corn-soy oil)
Number of subjects: 19
Study: 27430267

Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 588

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 588
Study: 24754607

Group type: EXPERIMENTAL
Intervention: Hands-on training
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Video training
Number of subjects: 0
Study: 23750963

Group type: EXPERIMENTAL
Intervention: Self-touch (hands touching feet) in anatomically incongruent condition (hands-parallel/feet-crossed)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Self-touch (hands touching feet) with feet active
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Self-touch (hands touching feet) with complex movement sequence
Number of subjects: 0

Group type: COMPARATOR
Intervention: Object-touch (not specified)
Number of subjects: 0
Study: 20023603

Group type: EXPERIMENTAL
Intervention: Surgical treatment
Number of subjects: 924

Group type: EXPERIMENTAL
Intervention: Nonoperative treatment
Number of subjects: 924
Study: 18494813

Group type: EXPERIMENTAL
Intervention: Self-monitoring of blood glucose (SMBG)
Number of subjects: 610

Group type: COMPARATOR
Intervention: Non-self-monitoring of blood glucose (non-SMBG)
Number of subjects: 610
Study: 17048434

Group type: COMPARATOR
Intervention: ZDV + ddI
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: ZDV + ddI + CHQ
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: ZDV + ddI (experienced children) + CHQ
Number of subjects: 55
Study: 12946037

Group type: EXPERIMENTAL
Intervention: Dietary salt intake (energy-adjusted quintiles)
Number of subjects: 120852

Group type: EXPERIMENTAL
Intervention: Salt added at the hot meal
Number of subjects: 120852

Group type: EXPERIMENTAL
Intervention: Bacon consumption
Number of subjects: 120852

Group type: EXPERIMENTAL
Intervention: Other sliced cold meat consumption
Number of subjects: 120852

Group type: EXPERIMENTAL
Intervention: Dietary salt and cured meat intake among subjects with self-reported stomach disorders
Number of subjects: 120852
Study: 11133338

Group type: EXPERIMENTAL
Intervention: $2 cash incentive
Number of subjects: 4200

Group type: EXPERIMENTAL
Intervention: $15 cash incentive
Number of subjects: 4200

Group type: EXPERIMENTAL
Intervention: $200 prize drawing incentive
Number of subjects: 4200

Group type: COMPARATOR
Intervention: No incentive
Number of subjects: 4200

Group type: EXPERIMENTAL
Intervention: Incentives (combined)
Number of subjects: 4200
Study: 9062526

Group type: EXPERIMENTAL
Intervention: Sucrose polyester
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Digestible fat
Number of subjects: 8

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 8
Study: 8230265

Group type: EXPERIMENTAL
Intervention: rIFN-gamma (0.2 mg, 4 x 10(6) units) once a day, subcutaneously, for 6 months
Number of subjects: 100

Group type: COMPARATOR
Intervention: Observation only (control group)
Number of subjects: 100
Study: 3777908

Group type: EXPERIMENTAL
Intervention: Oral administration of ciprofloxacin (200 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Intravenous administration of ciprofloxacin (200 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Both oral and intravenous administration of ciprofloxacin
Number of subjects: 12
Study: 31950482

Group type: COMPARATOR
Intervention: Phenylephrine (P group)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Saline (S group)
Number of subjects: 52
Study: 29122559

Group type: EXPERIMENTAL
Intervention: taVNS
Number of subjects: 10

Group type: COMPARATOR
Intervention: Sham stimulation (Cerbomed Nemos®)
Number of subjects: 10
Study: 27565897

Group type: EXPERIMENTAL
Intervention: AL + PQ (artemether-lumefantrine plus primaquine 0.25 mg/kg)
Number of subjects: 220

Group type: COMPARATOR
Intervention: AL (artemether-lumefantrine alone)
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: AL + PQ
Number of subjects: 220

Group type: COMPARATOR
Intervention: AL
Number of subjects: 220
Study: 25040945

Group type: EXPERIMENTAL
Intervention: Sitagliptin (100 mg/day, 6 weeks)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control (non-diabetic subjects)
Number of subjects: 47
Study: 22314053

Group type: EXPERIMENTAL
Intervention: Fruit & Veg $ense sessions and newsletters at weeks 2 and 5
Number of subjects: 292

Group type: COMPARATOR
Intervention: Control group (wait-list)
Number of subjects: 292

Group type: EXPERIMENTAL
Intervention: Fruit & Veg $ense sessions
Number of subjects: 292
Study: 20689074

Group type: EXPERIMENTAL
Intervention: SB‐681323, 7.5 mg daily for 28 days, starting 3 days before PCI
Number of subjects: 92

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study: 18296829

Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 57

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 57
Study: 16491814

Group type: EXPERIMENTAL
Intervention: Low dose doxycycline (20 mg, twice a day)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: High dose doxycycline (200 mg, twice a day)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 150
Study: 12397267

Group type: EXPERIMENTAL
Intervention: Patient-controlled sedation (propofol 4.8 mg and alfentanil 12 microg per bolus, no loading dose, lockout time set at zero)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Intravenous sedation (diazemuls 0.1 mg/kg and meperidine 0.5 mg/kg, with further increases at the discretion of the endoscopist)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Patient-controlled sedation
Number of subjects: 100

Group type: COMPARATOR
Intervention: Intravenous sedation
Number of subjects: 100
Study: 10325265

Group type: EXPERIMENTAL
Intervention: Laparoscopic myomectomy
Number of subjects: 115
Study: 8649053

Group type: EXPERIMENTAL
Intervention: Anthracyclines (ANT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Idarubicin (IDR)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Early dose-intensive ANT consolidation program
Number of subjects: 0
Study: 1960378

Group type: EXPERIMENTAL
Intervention: alpha-interferon (90 million units per m2 total dose over 12 weeks)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: alpha-interferon
Number of subjects: 114
Study: 7041145

Group type: EXPERIMENTAL
Intervention: Bandaged for three weeks
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Bandaged for six weeks (rebandaged after three weeks)
Number of subjects: 169
Study: 30946704

Group type: EXPERIMENTAL
Intervention: Brexpiprazole 0.5 to 3 mg/d (flexible dose) adjunct to current antidepressant treatment
Number of subjects: 2944
Study: 29939770

Group type: EXPERIMENTAL
Intervention: Vitamins (C: 1 g/day, E: 400 IU/day)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control
Number of subjects: 42
Study: 26846283

Group type: EXPERIMENTAL
Intervention: Methotrexate subcutaneous (MTX SC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Methotrexate oral (MTX OR)
Number of subjects: 0
Study: 24717626

Group type: EXPERIMENTAL
Intervention: Tadalafil 10 mg daily for 12 weeks
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Tadalafil 10 mg daily
Number of subjects: 120
Study: 22206073

Group type: EXPERIMENTAL
Intervention: Niacinamide/glycerin body moisturizers
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Other moisturizers
Number of subjects: 121

Group type: COMPARATOR
Intervention: No treatment control
Number of subjects: 121
Study: 20175345

Group type: EXPERIMENTAL
Intervention: 400 microg misoprostol
Number of subjects: 72

Group type: COMPARATOR
Intervention: Vitamin B6 placebo
Number of subjects: 72
Study: 17431725

Group type: EXPERIMENTAL
Intervention: Laparoscopic-assisted colonic J-pouch reconstruction
Number of subjects: 48

Group type: COMPARATOR
Intervention: Laparoscopic straight end-to-end anastomosis
Number of subjects: 48
Study: 14998964

Group type: EXPERIMENTAL
Intervention: Day 1 zygote transfer
Number of subjects: 254

Group type: COMPARATOR
Intervention: Day 3 cleavage stage embryo transfer
Number of subjects: 254
Study: 12495392

Group type: EXPERIMENTAL
Intervention: Early invasive strategy (n = 1114)
Number of subjects: 757

Group type: COMPARATOR
Intervention: Early conservative strategy (n = 1106)
Number of subjects: 757
Study: 9614605

Group type: EXPERIMENTAL
Intervention: Coping Skills Training (CST) with intensive management
Number of subjects: 65

Group type: COMPARATOR
Intervention: Intensive management without CST
Number of subjects: 65
Study: 8608069

Group type: EXPERIMENTAL
Intervention: Patient-controlled analgesia (PCA) with morphine (1.5-2 mg with a lockout of 5-10 minutes on demand)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Intramuscular (i.m.) morphine injection (0.15-0.2 mg/kg every 4 hours on demand)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Length of hospital stay following cholecystectomy
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Length of hospital stay following laminectomy
Number of subjects: 67
Study: 2510262

Group type: EXPERIMENTAL
Intervention: Rioprostil 300 micrograms
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Rioprostil 600 micrograms
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 799979

Group type: EXPERIMENTAL
Intervention: Lymecycline (204 mg, two capsules twice daily)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Amoxycillin (250 mg, three times daily)
Number of subjects: 132
Study: 30689901

Group type: EXPERIMENTAL
Intervention: Provision of intrauterine contraception
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 100
Study: 28592276

Group type: EXPERIMENTAL
Intervention: No mechanical ventilation during cardiopulmonary bypass
Number of subjects: 870

Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure of 5 cmH2O during cardiopulmonary bypass
Number of subjects: 870

Group type: EXPERIMENTAL
Intervention: Respiratory rate of 5 acts/min with tidal volume of 2-3 ml/Kg of ideal body weight and positive end-expiratory pressure of 3-5 cmH2O during cardiopulmonary bypass
Number of subjects: 870

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 870
Study: 26390920

Group type: EXPERIMENTAL
Intervention: Half-dose photodynamic therapy (PDT)
Number of subjects: 156

Group type: COMPARATOR
Intervention: High-density subthreshold micropulse laser treatment (HSML)
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Half-dose PDT
Number of subjects: 156

Group type: COMPARATOR
Intervention: HSML
Number of subjects: 156
Study: 24041010

Group type: EXPERIMENTAL
Intervention: Q-Pan (0.9 μg HA)
Number of subjects: 543

Group type: EXPERIMENTAL
Intervention: D-Pan (0.9 μg HA)
Number of subjects: 543

Group type: EXPERIMENTAL
Intervention: Q-Pan (1.9 μg HA)
Number of subjects: 543

Group type: COMPARATOR
Intervention: Q-Pan
Number of subjects: 543

Group type: COMPARATOR
Intervention: D-Pan
Number of subjects: 543
Study: 21837752

Group type: EXPERIMENTAL
Intervention: BMS‐790052 (1, 10, 30, 60, or 100 mg once daily or 30 mg twice daily)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: BMS‐790052
Number of subjects: 30
Study: 19293342

Group type: EXPERIMENTAL
Intervention: ARD-07 with food (0.5 mg/kg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: ARD-07 without food (0.5 mg/kg)
Number of subjects: 16
Study: 17227321

Group type: EXPERIMENTAL
Intervention: Insulin detemir
Number of subjects: 347

Group type: COMPARATOR
Intervention: NPH insulin
Number of subjects: 347
Study: 15693705

Group type: EXPERIMENTAL
Intervention: Extract A: caffeoylquinic acids equivalent to 107.0 mg caffeic acid and luteolin glycosides equivalent to 14.4 mg luteolin
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Extract B: caffeoylquinic acids equivalent to 153.8 mg caffeic acid and luteolin glycosides equivalent to 35.2 mg luteolin
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Luteolin administered as glucoside
Number of subjects: 14
Study: 11789734

Group type: EXPERIMENTAL
Intervention: Point-of-care testing (POCT) for prothrombin time (PT)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Point-of-care testing (POCT) for activated partial thromboplastin time (aPTT)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Antifibrinolytic agents (aprotinin, epsilon-aminocaproic acid)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 42
Study: 9814109

Group type: EXPERIMENTAL
Intervention: Surgical procedures for varicocele correction
Number of subjects: 66
Study: 8073778

Group type: EXPERIMENTAL
Intervention: Melbrosia
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 2913775

Group type: EXPERIMENTAL
Intervention: Prazosin
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 15

Group type: COMPARATOR
Intervention: Prazosin and Propranolol
Number of subjects: 15
Study: 30452928

Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg/day
Number of subjects: 1996

Group type: COMPARATOR
Intervention: Atorvastatin 10 mg/day
Number of subjects: 1996

Group type: EXPERIMENTAL
Intervention: Higher ln-transformed FGF21 levels at randomization
Number of subjects: 1996

Group type: EXPERIMENTAL
Intervention: Higher ln-transformed FGF21 levels at 1-year post-randomization
Number of subjects: 1996

Group type: EXPERIMENTAL
Intervention: Changes in FGF21 levels over 1-year
Number of subjects: 1996

Group type: EXPERIMENTAL
Intervention: FGF21 levels
Number of subjects: 1996
Study: 29212477

Group type: EXPERIMENTAL
Intervention: Nurse-led health and lifestyle modification program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 0
Study: 25455795

Group type: EXPERIMENTAL
Intervention: High intensity training (HI) with six booster sessions over 3 months
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: High intensity training (HI)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Moderate intensity training
Number of subjects: 34
Study: 23670995

Group type: EXPERIMENTAL
Intervention: Aerobic training
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Resistance training
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Combined training
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Increased estimated METs
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Increased estimated METs and reduced waist circumference
Number of subjects: 201
Study: 21272196

Group type: EXPERIMENTAL
Intervention: Aerobic training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Callisthenic exercise
Number of subjects: 0
Study: 19485587

Group type: EXPERIMENTAL
Intervention: Multisystemic therapy (MST)
Number of subjects: 127
Study: 15505645

Group type: EXPERIMENTAL
Intervention: Natural honey
Number of subjects: 20

Group type: COMPARATOR
Intervention: Eusol solution
Number of subjects: 20
Study: 10228190

Group type: EXPERIMENTAL
Intervention: 5 mg of infliximab per kilogram
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: 10 mg of infliximab per kilogram
Number of subjects: 94

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study: 15251577

Group type: EXPERIMENTAL
Intervention: hydrochlorothiazide
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: spironolactone
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: dextroamphetamine sulfate
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: captopril
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: dextroamphetamine sulfate (after nonamphetamine therapies)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: dextroamphetamine sulfate (urinary excretion <75%)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: dextroamphetamine sulfate (urinary excretion <55%)
Number of subjects: 200
Study: 2101059

Group type: EXPERIMENTAL
Intervention: Zopiclone (6.25, 8.75 and 11.25 mg)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Triazolam (0.1875, 0.375 and 0.5 mg)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Zopiclone 10 mg
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Triazolam 0.5 mg
Number of subjects: 14
Study: 6969081

Group type: EXPERIMENTAL
Intervention: Metocurine 0.45 mg kg‐1
Number of subjects: 20

Group type: COMPARATOR
Intervention: Pancuronium 0.1 mg kg‐1
Number of subjects: 20
Study: 30472236

Group type: EXPERIMENTAL
Intervention: Abrilumab 70 mg
Number of subjects: 354

Group type: EXPERIMENTAL
Intervention: Abrilumab 210 mg
Number of subjects: 354

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 354
Study: 28702870

Group type: EXPERIMENTAL
Intervention: Mindfulness (n = 86)
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: Hypnotic Suggestion (n = 73)
Number of subjects: 244

Group type: COMPARATOR
Intervention: Psychoeducation (n = 85)
Number of subjects: 244
Study: 26433959

Group type: EXPERIMENTAL
Intervention: Paclitaxel 90 mg/m(2), Cisplatin 40 mg/m(2)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Paclitaxel 90 mg/m(2), Cisplatin 50 mg/m(2)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Paclitaxel 105 mg/m(2), Cisplatin 50 mg/m(2)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Pelvic IMRT with concurrent TP
Number of subjects: 18
Study: 24268211

Group type: EXPERIMENTAL
Intervention: Implantable cardioverter defibrillator (ICD)
Number of subjects: 1100

Group type: COMPARATOR
Intervention: Amiodarone (600 mg/d for 10 days, then 200-400 mg/d until the end of the study)
Number of subjects: 1100

Group type: EXPERIMENTAL
Intervention: ICD
Number of subjects: 1100

Group type: COMPARATOR
Intervention: Amiodarone
Number of subjects: 1100
Study: 21332299

Group type: EXPERIMENTAL
Intervention: Constraint-Induced Movement Therapy (CIMT)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Neurodevelopmental Treatment (NDT)
Number of subjects: 20
Study: 19203392

Group type: EXPERIMENTAL
Intervention: 1500 mg of metformin daily
Number of subjects: 58

Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 58
Study: 17338714

Group type: EXPERIMENTAL
Intervention: Transient overdrive pacing (at 35 bpm above baseline) for 2 minutes upon standing
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control with backup pacing (60 bpm)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Transient overdrive pacing in OH patients with CI
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Transient overdrive pacing in OH patients without CI
Number of subjects: 62